Jian GuSedem Yener

Elias Jaime Porras

BUS6900

IP Strategy and ManagementNOVARTIS GROUP

Context

About Novartis Company

IP Portfolio IP strategy and

managementFuture plan for

Novartis Company

About Novartis Companymultinational pharmaceutical company was created in 1996 from the merger of Ciba-

Geigy (1860) and Sandoz Laboratories (1886). offers a wide range of healthcare products through

their Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health Divisions.

Is a full member of the European Federation of Pharmaceutical Industries and Associations.

It is Swiss company but main local is USA Cambridge.

La Jolla, there is Genetic Institute, researching new medicines.

In 1998 the company made headlines with its biotechnology licensing agreement with the UC Berkeley Department of Plant and Microbial Biology.

DetailsCEO :Dr. Daniel Vasella, M.D. Employees : 98,200 Market Cap : 107,150,055,000 Auditor : PriceWaterHouse

Cooperation A.G.Gross Margin : 71.3 MProfit Margin : 38.1 MEBIT Margin : 20.9 MReturn on Equity : 23.9 MReturn on Capital : 22.9 MReturn on Assets : 14.8 MInvestment : 6.8 M

Pharmaceuticals Products of Novartis Company (18)

Diovan- $5.0 B sales (2007)- Hypertension

Gleevec - $3.1 B- for Chronic myeloid leukemia

Zometa- $1.3 B (2007)- Cancer complications

Sandostatin - $1.0 B (2007) - Acromegaly

Sandimmun Neoral- $944 M (2007)- Transplantation

Femara- $937 M (2007)- Breast cancer

Lotrel- $748 M (2007)- Hypertension

Voltaren- $747 M (2007)- Inflammation

Trileptal- $692 M (2007)- Epilepsy

Lescol- $665 M (2007)- cholestrol

Exelon- $632 M (2007)- Alzheimer's disease

Comtan- $420 M (2007)- Parkinson's disease

Tegretol- $413 M (2007)- Epilepsy

Lucentis- $393 M (2007)- Age-related macular degeneration

Ritalin- $375 M (2007) - ADD Exjade- $357 M (2007) – Iron

chelatorTobramycin- $273 M (2007)-

Cystic fibrosisTermalgin - (Paracetamol and

compounds.) - Treatment of fever and light pain.

Major therapeutic areas:autoimmunity/

transplantation/ inflammatory disease

cardiovascular disease diabetes gastrointestinal disease infectious diseases musculoskeletal disease neuroscience oncology ophthalmology respiratory disease

Novartis IP portfolio!!!involves

coordination and quality control of biologics patenting and freedom-to-operate analysis across all disease areas, platforms, and functions within NIBR.

is Director of Intellectual Property

John T. LiPatents, Head, Biology & Biologics, Novartis Institutes forBiomedical ResearchNovartis In USA

Novartis IP portfolio and It’s Process!!!

operates in 140 countries and currently has 75 new treatments in the pipeline

More than 12,000 US Granted Patents. Patent Mapping Reports provide specific and

detailed insights into patenting activities of specific Fortune 500, NASDAQ and Novartis is in top 100.

Is gearing up to break new CSR ground, with a funding proposal for neglected disease research that advantages IP rights to strike a balance between corporate return on investment and the condition of fundamental treatments to penniless developing countries.

Novartis IP portfolio and It’s Process!!!

The International Patent Classification (IPC) is a hierarchical system in which the whole area of technology is divided into a range of sections, classes, subclasses and groups.

IPC (International Patent Classification ) (US Patent Classification) UPC NAICS (North American Industrial

Classification System) (this new, uniform, industry)

Future Planning Novartis is planning release 17 new pharmaceutical

products. They are going to spend more then $12M for investment and IP Strategy.

Novartis Buys Additional 51.7% Stake in Speedel company.

Make e-business partnership: World Online and Novartis plan together to build initially a pan-European portal and an e-commerce platform that will become the first of its kind within the healthcare and wellness arena.

30% Increase In US Supplies Of Fluvirin Influenza Vaccines And Delivery Of 40 Million Doses.

will be replaced by two Novartis execs who will oversee development in newly created roles.

Contacts with Novartis General Manager in Turkey

:Gundem BerkmenDirector of Neuroscience BF :

Selahattin SayganDirector of Marketing Strategy :Bahadir

Pakis Marketing and Sale Manager

:Ayten Polat

Thank you!!!

Any Question?